We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00262093
First Posted: December 6, 2005
Last Update Posted: July 25, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Beth Israel Deaconess Medical Center
Information provided by:
Hadassah Medical Organization
December 4, 2005
December 6, 2005
July 25, 2007
November 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00262093 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.

We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Observational
Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Pre-Eclampsia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
200
Not Provided
Not Provided

Inclusion Criteria:

  • Every delivery

Exclusion Criteria:

  • Preeclampsia or pregnancy induced hypertension
Sexes Eligible for Study: Female
Child, Adult, Senior
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00262093
PRIMIMULTI-HMO-CTIL
Not Provided
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Beth Israel Deaconess Medical Center
Principal Investigator: Yuval Bdolah, MD, MSc Hadassah-Hebrew University Medical School
Hadassah Medical Organization
November 2005